» Articles » PMID: 15870827

The Difference Between Observed and Expected Prevalence of MCAD Deficiency in The Netherlands: a Genetic Epidemiological Study

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2005 May 5
PMID 15870827
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Medium chain acyl coenzyme A dehydrogenase (MCAD) deficiency is assumed to be the most common inherited disorder of mitochondrial fatty acid oxidation. Few reports mention the difference between the expected and observed prevalence of MCAD deficiency on the basis of the carrier frequency in the population. We performed a population-wide retrospective analysis of all known MCAD-deficient patients in The Netherlands. In this study, the observed prevalence of MCAD deficiency in The Netherlands was 1/27 400 (95% confidence interval (CI) 1/23 000-1/33 900), significantly different from the expected prevalence of 1/12 100 (95% CI 1/8450-1/18 500). The observed prevalence of MCAD deficiency showed a remarkable north-south trend within the country. From the patients in this cohort, it can be observed that underdiagnosis contributes to a larger extent to the difference between the expected and observed prevalences of MCAD deficiency in our country, than reduced penetrance. We determined estimates of the segregation proportion in a cohort of 73 families under the assumption of complete ascertainment (p(LM) = 0.41, 95% CI 0.31-0.51) and single ascertainment (p(D) = 0.28, 95% CI 0.19-0.37). With the expectation-maximization algorithm, a third estimate was obtained (p(EM) = 0.28, 95% CI 0.20-0.37). The agreement between the latter two estimates supports incomplete selection and the segregation proportions were in agreement with normal mendelian autosomal recessive inheritance.

Citing Articles

Epidemiology of inherited metabolic disorders in newborn screening: insights from three years of experience in Southern Iran.

Salarian L, Ilkhanipoor H, Amirhakimi A, Afshar Z, Nahid S, Ardekani F Orphanet J Rare Dis. 2025; 20(1):84.

PMID: 40001143 PMC: 11853994. DOI: 10.1186/s13023-025-03602-w.


Living on the edge: substrate competition explains loss of robustness in mitochondrial fatty-acid oxidation disorders.

van Eunen K, Volker-Touw C, Gerding A, Bleeker A, Wolters J, van Rijt W BMC Biol. 2016; 14(1):107.

PMID: 27927213 PMC: 5142382. DOI: 10.1186/s12915-016-0327-5.


Neonatal screening for profound biotinidase deficiency in the Netherlands: consequences and considerations.

Wiltink R, Kruijshaar M, van Minkelen R, Onkenhout W, Verheijen F, Kemper E Eur J Hum Genet. 2016; 24(10):1424-9.

PMID: 27329734 PMC: 5027693. DOI: 10.1038/ejhg.2016.65.


Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Evaluation of Genotype-Phenotype Correlation in Patients Detected by Newborn Screening.

Gramer G, Haege G, Fang-Hoffmann J, Hoffmann G, Bartram C, Hinderhofer K JIMD Rep. 2015; 23:101-12.

PMID: 25940036 PMC: 4484909. DOI: 10.1007/8904_2015_439.


Medium-chain acyl-CoA deficiency: outlines from newborn screening, in silico predictions, and molecular studies.

Catarzi S, Caciotti A, Thusberg J, Tonin R, Malvagia S, la Marca G ScientificWorldJournal. 2013; 2013:625824.

PMID: 24294134 PMC: 3833120. DOI: 10.1155/2013/625824.